Form 8-K

8-K — HAEMONETICS CORP

Accession: 0000313143-26-000031

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0000313143

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — hae-20260507.htm (Primary)

EX-99.1 (ex991-q4mar2026earningsrel.htm)

GRAPHIC (newlogo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: hae-20260507.htm · Sequence: 1

hae-20260507

0000313143false00003131432026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts 001-14041 04-2882273

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common stock, $.01 par value per share HAE New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description

99.1

Press Release of Haemonetics Corporation dated May 7, 2026 announcing financial results for the fourth quarter and fiscal year ended March 28, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date : May 7, 2026 By: /s/ Christopher A. Simon

Name: Christopher A. Simon

Title: President and Chief Executive Officer

EX-99.1

Filename: ex991-q4mar2026earningsrel.htm · Sequence: 2

Document

Exhibit 99.1

Investor Contacts Media Contact

Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director- Global Communications

(781) 356-9763 (781) 356-9776

olga.guyette@haemonetics.com josh.gitelson@haemonetics.com

David Trenk, Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports Fourth Quarter and Fiscal 2026 Results;

Provides Fiscal 2027 Guidance

Boston, MA, May 7, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026:

Fourth Quarter Fiscal 2026 Fiscal 2026

Revenue, increase/(decrease)

$346 million, 4.8%

$1.334 billion, (2.0)%

Organic(1) revenue increase

4.5% 1.1%

Organic ex-CSL(2) revenue increase

8.6% 9.5%

(Loss) earnings per diluted share

$(0.44) $2.05

Adjusted earnings per diluted share

$1.29 $4.96

Cash flow from operating activities

$71 million $293 million

Free cash flow

$45 million $210 million

__________

(1) Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. The Company's acquisition of Vivasure Medical Limited ("Vivasure") in January 2026 had no impact on organic revenue growth rates and is not separately quantified.

(2) In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Chris Simon, Haemonetics’ CEO, stated: "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."

GAAP RESULTS

Fourth quarter fiscal 2026 revenue was $346.4 million, up 4.8% compared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows:

Fourth Quarter Fiscal 2026 Reported

(Dollars in Millions)

Plasma $130.3 2.8%

Blood Center $56.4 0.7%

Hospital $159.6 8.0%

Total net revenue $346.4 4.8%

Gross margin was 57.2% in the fourth quarter of fiscal 2026, compared with 58.4% in the fourth quarter of fiscal 2025. The primary driver of the decrease in the gross margin percentage was a charge taken for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, partially offset by decreased restructuring costs related to portfolio rationalization initiatives and decreased amortization of fair value inventory step-up.

Operating expenses in the fourth quarter of fiscal 2026 were $221.2 million, an increase of $99.5 million, or 81.8%, when compared with the prior year period, driven by the impairment of intangible assets related to Attune Medical, partially offset by remeasurements of contingent consideration. Due to these charges, the Company had operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million and an operating margin of 21.6% in the fourth quarter of fiscal 2025. The income tax rates were 29.1% and 18.0% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively. Additionally, due to the charges above, fourth quarter fiscal 2026 net loss and loss per diluted share were $20.1 million and $(0.44), respectively, compared with net income and earnings per diluted share of $58.0 million and $1.17, respectively, in the fourth quarter of fiscal 2025.

ADJUSTED RESULTS

Fourth quarter fiscal 2026 organic revenue growth was 4.5% and organic ex-CSL revenue growth was 8.6% compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:

Fourth Quarter Fiscal 2026

Organic Organic ex-CSL

Plasma 1.8% 12.7%

Blood Center 5.5% 5.5%

Hospital 6.5% 6.5%

Total net revenue 4.5% 8.6%

Fourth quarter fiscal 2026 adjusted gross margin was 59.7%, down 50 basis points compared with the prior year period. The primary drivers for the decrease in adjusted gross margin percentage were less favorable mix and impacts from tariffs, partially offset by higher volume and pricing benefits.

Adjusted operating expenses were $122.2 million, up $5.5 million, or 4.7%, when compared with the prior year period. The increase in adjusted operating expenses was largely driven by the acquisition of Vivasure, impacts from tariff and performance-based compensation as well as additional growth investments. Adjusted operating income for the fourth quarter of fiscal 2026 was $84.5 million, up $2.2 million or 2.6%, and adjusted operating margin was 24.4%, down 50 basis points, compared with the same period of fiscal 2025. The adjusted income tax rates were 24.8% and 22.2% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively.

Fourth quarter fiscal 2026 adjusted net income was $59.7 million, down $1.8 million, or 3.0%, and adjusted earnings per diluted share was $1.29, up 4.0%, each when compared with the same period of fiscal 2025.

BALANCE SHEET AND CASH FLOW

Cash on hand at March 28, 2026 was $245.4 million, a decrease of $61.3 million since March 29, 2025, primarily driven by cash outflows for the acquisition of Vivasure and share repurchases, partially offset by cash flow provided from operating activities.

Fourth quarter fiscal 2026 cash flows from operating activities was $70.9 million, down $45.6 million, or 39.1%, and free cash flow was $44.5 million, down $50.4 million, or 53.1%, each when compared with the same period of fiscal 2025. The primary driver of decreased operating cash flow and free cash flow as compared to the same period of fiscal 2025 was the timing of income taxes paid and unfavorable working capital adjustments driven by the timing of cash collections.

SHARE REPURCHASE PROGRAM

As part of its previously announced $500.0 million share repurchase program, the Company repurchased 1,579,255 shares of its common shares for $100.0 million during the fourth quarter of fiscal 2026. Specifically, the Company repurchased 360,457 shares for $25.0 million pursuant to a Rule 10b5-1 trading plan and subsequently repurchased 1,218,798 shares for $75.0 million pursuant to an accelerated share repurchase agreement entered into with Goldman, Sachs & Co. The total remaining authorization for repurchases of the Company’s common stock under the 2025 share repurchase program is $325.0 million.

FISCAL 2027 GUIDANCE

The Company issued its fiscal 2027 GAAP total revenue and organic revenue growth guidance as follows:

Total Company

Reported Revenue 4 - 7%

53rd week impact (~2%)

Currency impact 0 - 1%

Organic Revenue(1)

3 - 6%

Adjusted operating margin 50 – 100 bps expansion YoY

Adjusted earnings per diluted share Comparable to revenue growth

Free cash flow conversion(2)

~80%

__________

(1) Includes approximately mid-single-digit growth in each of Plasma and Hospital and a mid-single-digit decline in Blood Center. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance.

(2) Free cash flow conversion is calculated as free cash flow divided by adjusted net income.

WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS

The Company will host a conference call with investors and analysts to discuss fourth quarter and full year fiscal 2026 results on Thursday, May 7, 2026 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register-conf.media-server.com/register/BI5821cb82b2104f4f8171096b52ca101c. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/7d678otf.

The Company has also provided a supplemental earnings presentation for its fourth quarter of fiscal 2026, which is available on its website and can be found at the following direct link: https://haemonetics.gcs-web.com/static-files/a9288d0a-0c42-4d85-a9f1-ac16ee243161.

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

FORWARD-LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.

MANAGEMENT’S USE OF NON-GAAP MEASURES

This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this release, organic revenue growth excludes the impact of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. Organic ex-CSL revenue growth further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, digital transformation costs, amortization of acquired intangible assets, asset impairments and write downs, amortization of fair value inventory step-up, costs related to compliance with the European Union Medical Device Regulation ("MDR") and In Vitro Diagnostic Regulation ("IVDR"), acquisition, integration and divestiture related costs, net gains on the repurchase of convertible notes, gains on sales of property, plant and equipment, certain tax settlements, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.

Haemonetics Corporation Financial Summary

Condensed Consolidated Statements of (Loss) Income (Unaudited)

Three Months Ended Twelve Months Ended

3/28/2026 3/29/2025 Inc/(Dec) % 3/28/2026 3/29/2025 (Dec)/Inc %

(Data and Shares in Thousands, Except Per Share Data) (Data and Shares in Thousands, Except Per Share Data)

Net revenues $ 346,351 $ 330,599 4.8% $ 1,334,027 $ 1,360,824 (2.0)%

Cost of goods sold 148,139 137,549 7.7% 546,441 611,866 (10.7)%

Gross profit 198,212 193,050 2.7% 787,586 748,958 5.2%

Research and development 14,446 15,914 (9.2)% 59,766 62,722 (4.7)%

Selling, general and administrative 121,828 115,360 5.6% 442,421 436,789 1.3%

Amortization of acquired intangible assets 10,491 11,296 (7.1)% 43,998 48,261 (8.8)%

Remeasurement of contingent consideration (2,774) (20,855) (86.7)% (1,879) (23,022) (91.8)%

Impairment of intangible assets 77,246 — 100.0% 86,546 2,391 3519.7%

Total operating expenses 221,237 121,715 81.8% 630,852 527,141 19.7%

Operating (loss) income (23,025) 71,335 (132.3)% 156,734 221,817 (29.3)%

Interest and other expense, net (5,374) (598) 798.7% (28,704) (9,746) 194.5%

(Loss) income before (benefit) provision for income taxes (28,399) 70,737 (140.1)% 128,030 212,071 (39.6)%

(Benefit) provision for income taxes (8,252) 12,756 (164.7)% 30,722 44,392 (30.8)%

Net (loss) income $ (20,147) $ 57,981 (134.7)% $ 97,308 $ 167,679 (42.0)%

Net (loss) income per share assuming dilution $ (0.44) $ 1.17 (137.6)% $ 2.05 $ 3.31 (38.1)%

Weighted average number of shares:

Basic 46,224 49,193 47,179 50,330

Diluted 46,224 49,476 47,354 50,730

Profit Margins: (Dec)/Inc % Inc/(Dec) %

Gross profit 57.2 % 58.4 % (1.2)% 59.0 % 55.0 % 4.0%

Research and development 4.2 % 4.8 % (0.6)% 4.5 % 4.6 % (0.1)%

Selling, general and administrative 35.2 % 34.9 % 0.3% 33.2 % 32.1 % 1.1%

Operating (loss) income (6.6) % 21.6 % (28.2)% 11.7 % 16.3 % (4.6)%

(Loss) income before (benefit) provision for income taxes (8.2) % 21.4 % (29.6)% 9.6 % 15.6 % (6.0)%

Net (loss) income (5.8) % 17.5 % (23.3)% 7.3 % 12.3 % (5.0)%

Revenue Analysis by Business Unit (Unaudited)

Three Months Ended

3/28/2026 3/29/2025 Reported growth Currency impact

Acquisitions & Divestitures(1)

Organic growth(1)

2025 CSL US Disposable Revenue(2)

Organic growth, ex-CSL

(Dollars in Thousands)

Revenues by business unit

Plasma $ 130,290 $ 126,736 2.8 % 1.0 % — % 1.8 % (10.9) % 12.7 %

Apheresis 56,414 54,320 3.9 % 1.7 % (3.3) % 5.5 % — % 5.5 %

Whole Blood — 1,686 (100.0) % — % (100.0) % — % — % — %

Blood Center 56,414 56,006 0.7 % 1.5 % (6.3) % 5.5 % — % 5.5 %

Interventional Technologies(3)

60,397 66,799 (9.6) % 0.7 % — % (10.3) % — % (10.3) %

Blood Management Technologies(4)

99,250 81,058 22.4 % 1.9 % — % 20.5 % — % 20.5 %

Hospital 159,647 147,857 8.0 % 1.5 % — % 6.5 % — % 6.5 %

Total net revenues $ 346,351 $ 330,599 4.8 % 1.3 % (1.0) % 4.5 % (4.1) % 8.6 %

Twelve Months Ended

3/28/2026 3/29/2025 Reported growth Currency impact

Acquisitions & Divestitures(1)

Organic growth(1)

2025 CSL US Disposable Revenue(2)

Organic growth, ex-CSL

(Dollars in Thousands)

Revenues by business unit

Plasma $ 524,456 $ 535,431 (2.0) % 0.7 % — % (2.7) % (22.3) % 19.6 %

Apheresis 220,861 213,134 3.6 % 1.4 % (2.3) % 4.5 % — % 4.5 %

Whole Blood 406 47,990 (99.2) % (0.1) % (99.1) % — % — % — %

Blood Center 221,267 261,124 (15.3) % 1.2 % (21.0) % 4.5 % — % 4.5 %

Interventional Technologies(3)

234,007 255,019 (8.2) % 0.5 % — % (8.7) % — % (8.7) %

Blood Management Technologies(4)

354,297 309,250 14.6 % 1.1 % — % 13.5 % — % 13.5 %

Hospital 588,304 564,269 4.3 % 0.8 % — % 3.5 % — % 3.5 %

Total net revenues $ 1,334,027 $ 1,360,824 (2.0) % 0.8 % (3.9) % 1.1 % (8.4) % 9.5 %

__________

(1) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 and the impact of the exit of certain liquid solution products. The Company's acquisition of Vivasure in January 2026 had no impact on total Company or business unit organic revenue growth rates and is not separately quantified.

(2) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

(3) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.

(4) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.

Condensed Consolidated Balance Sheets (Unaudited)

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Assets

Cash and cash equivalents $ 245,440 $ 306,763

Accounts receivable, net 216,855 202,657

Inventories, net 306,370 365,141

Other current assets 66,214 60,414

Total current assets 834,879 934,975

Property, plant & equipment, net 305,761 284,052

Intangible assets, net 447,655 455,743

Goodwill 656,368 604,269

Other assets 151,262 171,909

Total assets $ 2,395,925 $ 2,450,948

Liabilities & Stockholders' Equity

Short-term debt & current maturities $ 5,015 $ 303,558

Other current liabilities 277,584 274,555

Total current liabilities 282,599 578,113

Long-term debt 1,219,565 921,230

Other long-term liabilities 97,441 130,769

Stockholders' equity 796,320 820,836

Total liabilities & stockholders' equity $ 2,395,925 $ 2,450,948

Condensed Consolidated Statements of Cash Flows (Unaudited)

Twelve Months Ended

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Cash Flows from Operating Activities:

Net income $ 97,308 $ 167,679

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 111,717 115,586

Amortization of fair value inventory step-up 5,814 14,956

Share-based compensation expense 33,827 29,636

Impairment of intangible assets 86,546 2,391

Gain on repurchase of convertible senior notes, net — (12,600)

Gains on sales of property, plant and equipment (714) (15,698)

Deferred income taxes (26,471) (5,219)

Remeasurement of contingent consideration (1,879) (23,022)

Change in other non-cash operating activities 10,726 9,978

Change in operating assets and liabilities

Change in accounts receivable, net (14,881) 6,956

Change in inventories, net 47,361 (64,704)

Change in prepaid income taxes (4,534) 226

Change in other assets and other liabilities (35,028) (25,232)

Change in accounts payable and accrued expenses (16,571) (19,208)

Net cash provided by operating activities 293,221 181,725

Cash Flows from Investing Activities:

Capital expenditures (32,780) (39,278)

Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (51,891) (21,112)

Proceeds from divestiture and sale of assets — 43,291

Proceeds from sale of property, plant and equipment 1,375 23,253

Acquisitions (60,180) (150,906)

Other investments (36,071) (17,143)

Net cash used in investing activities (179,547) (161,895)

Cash Flows from Financing Activities:

Repayments, net of borrowings (6,250) 447,312

Purchase of capped call related to convertible notes — (88,200)

Debt issuance costs — (23,135)

Share repurchase (175,000) (225,000)

Proceeds from employee stock programs 7,893 8,333

Cash used to net share settle employee equity awards (5,001) (10,243)

Other financing activities (102) (249)

Net cash (used in) provided by financing activities (178,460) 108,818

Effect of exchange rates on cash and cash equivalents 3,463 (685)

Net Change in Cash and Cash Equivalents (61,323) 127,963

Cash and Cash Equivalents at Beginning of the Period 306,763 178,800

Cash and Cash Equivalents at End of Period $ 245,440 $ 306,763

Free Cash Flow Reconciliation:

Cash provided by operating activities $ 293,221 $ 181,725

Capital expenditures (32,780) (39,278)

Additions to Haemonetics equipment (51,891) (21,112)

Proceeds from sale of property, plant and equipment 1,375 23,253

Free cash flow $ 209,925 $ 144,588

Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited)

Gross profit Operating expenses Operating (loss) income Interest and other (expense) income (Benefit) provision for income taxes Net (loss) income

(Loss) earnings per diluted share(1)(2)

Three Months Ended March 28, 2026:

(Dollars in Thousands, Except Per Share Data)

Reported $ 198,212 $ 221,237 $ (23,025) $ (5,374) $ (8,252) $ (20,147) $ (0.44)

Amortization of acquired intangible assets — (10,491) 10,491 — 2,471 8,020 0.17

Acquisition, integration and transaction costs 1,077 (8,296) 9,373 294 2,247 7,420 0.16

Restructuring costs 77 (119) 196 — 48 148 —

Restructuring related costs (94) (50) (44) — — (44) —

Digital transformation costs — (5,004) 5,004 — 1,250 3,754 0.08

Write down of certain assets — (172) 172 — 86 86 —

Litigation-related charges — (443) 443 — 107 336 0.01

Impairment of intangible assets — (77,246) 77,246 — 18,984 58,262 1.26

Remeasurement of contingent consideration — 2,774 (2,774) — (1,278) (1,496) (0.03)

Provision for pre-acquisition inventory and inventory purchase commitments 7,419 — 7,419 — 1,898 5,521 0.12

Discrete tax items — — — — 2,129 (2,129) (0.04)

Adjusted $ 206,691 $ 122,190 $ 84,501 $ (5,080) $ 19,690 $ 59,731 $ 1.29

Adjusted, as a percentage of net revenues 59.7 % 35.3 % 24.4 % 17.2 %

__________

(1) GAAP net loss per share is calculated using weighted average basic shares outstanding and excludes the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect.

(2) Adjusted net income per share is calculated using weighted average diluted shares outstanding of 46,411 which includes the impact of outstanding stock awards.

Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings (loss) per diluted share

Three Months Ended March 29, 2025:

(Dollars in Thousands, Except Per Share Data)

Reported $ 193,050 $ 121,715 $ 71,335 $ (598) $ 12,756 $ 57,981 $ 1.17

Amortization of acquired intangible assets — (11,296) 11,296 — 2,805 8,491 0.17

Amortization of fair value inventory step-up 2,637 — 2,637 — 641 1,996 0.04

Acquisition, integration and divestiture related costs 2,407 (4,882) 7,289 (2,559) 1,278 3,452 0.06

Restructuring costs 170 (814) 984 — 321 663 0.01

Restructuring related costs 790 (898) 1,688 — 386 1,302 0.03

Digital transformation costs — (4,450) 4,450 — 1,045 3,405 0.07

MDR and IVDR costs 13 (1,686) 1,699 — 404 1,295 0.03

Litigation-related charges — (1,820) 1,820 — 442 1,378 0.03

Remeasurement of contingent consideration — 20,855 (20,855) — (70) (20,785) (0.42)

Discrete tax adjustments — — — — (2,396) 2,396 0.05

Adjusted $ 199,067 $ 116,724 $ 82,343 $ (3,157) $ 17,612 $ 61,574 $ 1.24

Adjusted, as a percentage of net revenues 60.2 % 35.3 % 24.9 % 18.6 %

Reconciliation of Adjusted Measures for Year-to-Date FY26 and FY25 (Unaudited)

Gross profit Operating expenses Operating income (loss) Interest and other (expense) income Provision (benefit) for income taxes Net income (loss) Earnings (loss) per diluted share

Year Ended March 28, 2026:

(Dollars in Thousands, Except Per Share Data)

Reported $ 787,586 $ 630,852 $ 156,734 $ (28,704) $ 30,722 $ 97,308 $ 2.05

Amortization of acquired intangible assets — (43,998) 43,998 — 10,801 33,197 0.70

Amortization of fair value inventory step-up 5,814 — 5,814 — 1,427 4,387 0.09

Acquisition, integration and transaction costs 3,709 (10,446) 14,155 2,316 3,952 12,519 0.26

Restructuring costs (496) (3,610) 3,114 — 827 2,287 0.05

Restructuring related costs (33) (137) 104 — 26 78 —

Digital transformation costs — (21,526) 21,526 — 5,208 16,318 0.34

Write downs of certain assets — (1,006) 1,006 — 288 718 0.02

Litigation-related charges — 31 (31) — (8) (23) —

Impairment of intangible assets — (86,546) 86,546 — 21,253 65,293 1.38

Remeasurement of contingent consideration — 1,879 (1,879) — (898) (981) (0.02)

Provision for pre-acquisition inventory and inventory purchase commitments 7,419 — 7,419 — 1,884 5,535 0.12

Discrete tax items — — — — 1,933 (1,933) (0.03)

Adjusted $ 803,999 $ 465,493 $ 338,506 $ (26,388) $ 77,415 $ 234,703 $ 4.96

Adjusted, as a percentage of net revenues 60.3 % 34.9 % 25.4 % 17.6 %

Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings (loss) per diluted share

Year Ended March 29, 2025:

(Dollars in Thousands; Except Per Share Data)

Reported $ 748,958 $ 527,141 $ 221,817 $ (9,746) $ 44,392 $ 167,679 $ 3.31

Amortization of acquired intangible assets — (48,261) 48,261 — 11,986 36,275 0.72

Amortization of fair value inventory step-up 14,956 — 14,956 — 3,646 11,310 0.22

Acquisition, integration and divestiture related costs 3,204 (19,700) 22,904 (2,484) 2,415 18,005 0.35

Restructuring costs 11,328 (2,585) 13,913 — 3,477 10,436 0.21

Restructuring related costs 3,304 (3,941) 7,245 — 1,690 5,555 0.11

Digital transformation costs — (20,273) 20,273 — 4,818 15,455 0.30

PCS2 related charges — (4,000) 4,000 — 971 3,029 0.06

MDR and IVDR costs 13 (4,810) 4,823 — 1,144 3,679 0.07

Litigation-related charges — (2,877) 2,877 — 699 2,178 0.04

Gain on repurchase of convertible notes, net — — — (12,600) (3,059) (9,541) (0.19)

Gain on sale of property, plant and equipment — 14,134 (14,134) — (3,432) (10,702) (0.21)

Impairment of intangible assets — (2,391) 2,391 — 581 1,810 0.04

Remeasurement of contingent consideration — 23,022 (23,022) — (70) (22,952) (0.45)

Discrete tax items — — — — 707 (707) (0.01)

Adjusted $ 781,763 $ 455,459 $ 326,304 $ (24,830) $ 69,965 $ 231,509 $ 4.57

Adjusted, as a percentage of net revenues 57.4 % 33.5 % 24.0 % 17.0 %

GRAPHIC

Filename: newlogo.jpg · Sequence: 6

Binary file (455214 bytes)

Download newlogo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

May 07, 2026

Cover [Abstract]

Document Type

8-K

Entity Registrant Name

HAEMONETICS CORPORATION

Entity Central Index Key

0000313143

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity Incorporation, State or Country Code

Entity File Number

001-14041

Entity Tax Identification Number

04-2882273

Entity Address, Address Line One

125 Summer Street

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02110

City Area Code

781

Local Phone Number

848-7100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $.01 par value per share

Trading Symbol

HAE

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration